FURESTEM-OA-Kit injection for knee osteoarthritis in people who earlier received placebo
Tests FURESTEM-OA-Kit in adults with knee osteoarthritis who previously received placebo.
Key facts
- Who runs it
- Kang Stem Biotech Co., Ltd.
- Where
- Seoul, South KoreaSee the 2 sites
- Trial code
- Registry title
- A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial
- Status
- Recruiting
- People taking part
- 36 people, planned
- Started
- 20 Jul 2026
- Expected to end
- 28 Feb 2032
- Type of study
- Observational
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with knee osteoarthritis who got placebo (a dummy treatment) in the K0701 trial. They must also have finished its long-term follow-up study.
- Age
- 19 Years and older
- Sex
- All sexes
- Disease stage
- Knee osteoarthritis
- Earlier treatment
- Must have received placebo in the K0701 clinical trial and completed the long-term follow-up study.
Main reasons for not taking part
- The study doctor judges the person should not take part in this extension study
- Pregnant or breastfeeding women
- Women who could become pregnant, or men, who do not agree to use birth control during the study
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Participants who received placebo in the K0701 clinical trial and completed the Long-term follow-up study
- Participants who voluntarily provide written informed consent to participate in this extension study
Who cannot take part
- Participants meeting any of the following criteria:
- Participants whom the investigator considers unsuitable for participation in this extension study
- Pregnant or breastfeeding women, and women of childbearing potential or men who do not agree to use an appropriate method of contraception during the study
Where in South Korea
- CHA University Bundang Medical CenterSeoul, South KoreaContact: Jae Young Park, professorTaking people
- Kyung Hee University HospitalSeoul, South KoreaContact: Kyoung Ho Yoon Yoon, professor (principal investigator)Not yet recruiting
About the trial
What the trial wants to find out
A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial
- Plain-language title
- FURESTEM-OA-Kit injection for knee osteoarthritis in people who earlier received placeboGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 August 2026